Reata Pharmaceuticals, Inc. is a pharmaceutical company based in Plano, Texas. Founded in 2002, it is primarily focused on investigating experimental oral antioxidative and anti-inflammatory drugs,[2] which dually activate the antioxidative transcription factor Nrf2 and inhibit the pro-inflammatory transcription factor NF-κB.[3]
In July 2023, it was announced Reata had been acquired by the Cambridge, Massachusetts-headquartered multinationalbiotechnology company, Biogen for nearly $6.5 billion.[4] The purchase was completed on September 26 and Reata stock was delisted from the Nasdaq.[5]
Omaveloxolone (RTA 408) is a second generation member of the synthetic oleanane triterpenoid compounds and currently in clinical development. Preclinical studies have demonstrated that RTA 408 possesses antioxidative and anti-inflammatory activities,[12][13] as well as the potential to improve mitochondrial bioenergetics.[14] Because of the broad applicability of such effects across many diseases, RTA 408 is currently under clinical investigation in several Phase 2 clinical studies including immunooncology,[15]corneal endothelial cell loss associated with cataract surgery[16]Friedreich’s ataxia,[17] and mitochondrial myopathies.[18][19]
Reata is also actively engaged in the discovery of small molecule disease-modifying drugs that function by stabilizing the normal three-dimensional structure of target proteins or generally enhancing the folding environment of the cell. Defects in protein folding underlie a large number of genetic diseases including certain forms of cancer, familial Alzheimer's disease, and cystic fibrosis. Protein folding defects are also believed to play important roles in the development of non-inherited forms of many of these diseases.
Reata also has a licensing agreement with Abbvie for development and commercialization of bardoxolone methyl outside the U.S., excluding Asian markets defined in the agreement with Kyowa Hakko Kirin.[21]Abbvie and Reata also have a second agreement for development of the second generation portfolio of synthetic oleanane triterpenoid compounds, including RTA 408, as well as other Nrf2 activators.[22]
^Reisman SA, Lee CY, Meyer CJ, et al. (2014). "Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin". Arch Dermatol Res. 306 (5): 447–57. doi:10.1007/s00403-013-1433-7. PMID24362512. S2CID25733020.
US $26.52 million (2019)
US $53.59 million (2018)[1]
